Volume 13, Number 11—November 2007
    
    Research
Human Salmonella and Concurrent Decreased Susceptibility to Quinolones and Extended-Spectrum Cephalosporins
Table 3
Susceptibility results for NARMS non-Typhi Salmonella isolates with decreased susceptibility to quinolones and extended-spectrum cephalosporins, United States, 1996–2004*
| Isolate | Resistance | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| NAL | CIP | XNL | CRO | TAZ | TAZ/ CLAV | FOT | FOT/ CLAV | Other† | |
| AM18280 | >32 | 0.25 | >8 | 16 | 32 | 16/4 | 16 | 8/4 | AMP, AMC, CHL, FOX, KAN, STR, SUL, SXT, TET | 
| AM09124 | >32 | 0.5 | 2 | <0.25 | 0.5 | 0.25/4 | 0.25 | 0.12/4 | ND | 
| AM15266 | >32 | 0.5 | 2 | <0.25 | 0.5 | 0.25/4 | 0.25 | 0.12/4 | (CHL) | 
| AM12389 | >32 | 0.5 | 2 | <0.25 | 0.25 | 0.25/4 | 0.1 | 0.12/4 | (CHL), SUL, SXT, TET | 
| AM15010 | 16 | 0.25 | 8 | 8 | 64 | 0.5/4 | 4 | 0.25/4 | AMP, (CHL), SUL, SXT | 
| AM03005 | 16 | 0.25 | 2 | 0.5 | 0.25 | 0.12/4 | 0.12 | ≤0.06/4 | AMP, AMC, CHL, FOX, (GEN), KAN, STR, SUL, SXT | 
| AM15201 | >32 | 0.12 | >8 | 8 | 16 | 16/4 | 16 | 8/4 | AMP, AMC, CHL, FOX, STR, SUL, TET | 
| AM21465 | >32 | 0.12 | >8 | 16 | 16 | 16/4 | 8 | 8/4 | AMP, AMC, CHL, FOX, STR, SUL, TET | 
| AM20428 | >32 | 0.5 | 2 | <0.25 | 0.5 | 0.5/4 | 0.5 | 0.12/4 | (CHL), (FOX) | 
| AM06960 | >32 | >4 | 8 | 8 | 0.5 | 0.25/4 | 1 | 0.12/4 | AMP, AMC, (CHL), GEN, KAN, STR, SUL, SXT | 
| AM08081 | >32 | >4 | 4 | 0.5 | 0.5 | 0.25/4 | 1 | 0.12/4 | AMP, AMC, CHL, FOX, (GEN), KAN, STR, SUL, SXT | 
| AM08208 | >32 | >4 | 2 | <0.25 | 0.5 | 0.25/4 | 0.5 | 0.25/4 | AMP, (AMC) CHL, GEN, KAN, STR, SUL, SXT, TET | 
| AM09864 | >32 | >4 | 8 | 8 | 64 | 0.25/4 | 8 | 0.25/4 | AMP, (CHL), (FOX), GEN, KAN | 
| AM11007 | >32 | >4 | 4 | 0.5 | 1 | 0.5/4 | 1 | 0.5/4 | AMP, AMC, CHL, (FOX), KAN, SUL | 
| AM14058 | >32 | >4 | >8 | >64 | 64 | 64/4 | 128 | >64/4 | (AMI), AMP, AMC, CHL, FOX, KAN, SUL | 
| AM16094 | >32 | >4 | 4 | <0.25 | 0.5 | 0.25/4 | 1 | 0.25/4 | AMP, (AMC), CHL, (FOX), (GEN), KAN, SUL, SXT | 
| AM18622 | >32 | >4 | 8 | 1 | 2 | 0.5/4 | 4 | 0.5/4 | AMP, AMC, CHL, KAN, STR, SUL, SXT | 
| AM19422 | >32 | >4 | 4 | <0.25 | 0.5 | 0.5/4 | 2 | 0.25/4 | AMP, AMC, (GEN), KAN, STR, SUL, SXT | 
| AM20227 | >32 | >4 | 2 | <0.25 | 1 | 2/4 | 1 | 0.5/4 | AMP, AMC, (CHL), (FOX), GEN, KAN, STR, SUL, SXT | 
| AM20256 | >32 | >4 | 4 | <0.25 | 0.5 | 0.5/4 | 1 | 0.25/4 | AMP, (AMC), (CHL), (GEN), KAN, SUL, SXT | 
| AM02544 | 256 | 0.25 | >16 | 64 | 128 | 0.5/4 | 32 | 0.12/4 | AMP, (AMC), KAN, STR, SUL, TET | 
| AM08739 | >32 | 0.25 | >8 | 32 | 16 | 16/4 | 16 | 8/4 | AMP, AMC, CHL, FOX, GEN, KAN, STR, SUL, TET | 
| AM11682 | >32 | 0.25 | >8 | 16 | 16 | 8/4 | 16 | 8/4 | AMP, AMC, FOX | 
| AM14364 | >32 | 0.25 | >8 | 32 | 32 | 16/4 | 32 | 16/4 | AMP, AMC, CHL, FOX, GEN, KAN, STR, SUL, TET | 
| AM14807 | >32 | 0.25 | >8 | 16 | 32 | 16/4 | 16 | 32/4 | AMP, AMC, CHL, FOX, STR, SUL, TET | 
| AM20205 | >32 | 0.25 | 2 | <0.25 | 0.5 | 0.5/4 | 0.25 | 0.25/4 | AMP, KAN, STR, SUL, TET | 
| AM19537 | >32 | 0.12 | >8 | 16 | 16 | 16/4 | 8 | 8/4 | AMP, AMC, CHL, FOX, (GEN), (KAN), STR, SUL TET | 
*NARMS, National Antimicrobial Resistance Monitoring System; NAL, nalidixic acid; CIP, ciprofloxacin; XNL, ceftiofur; CRO, ceftriaxone; TAZ, ceftazidime; TAZ/CLAV, ceftazidime/clavulanate; FOT, cefotaxime, FOT/CLAV, cefotaxime/clavulanate; AMP, ampicillin; AMC, amoxicillin/clavulanate; CHL, chloramphenicol; FOX, cefoxitin; KAN, kanamycin; STR, streptomycin; SUL, sulfamethoxazole or sulfisoxazole; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline; AMI, amikacin; GEN, gentamicin.
†Drugs in parentheses had intermediate results.
1Current affiliation: Banfield, The Pet Hospital, Philadelphia, Pennsylvania, USA
2Current affiliation: Washington State University, Pullman, Washington, USA
